Nobel Ilac A.S

nobel.com.tr

Nobel İlaç has been active in the international market with a national capital from 1964 until today and develops pioneer and novelist products which increases the life quality by using the resources productively with the principle of being a worldwide trustworthy organization.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MARINUS PHARMACEUTICALS EARNS RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR GANAXOLONE TREATING CDKL5 DEFICIENCY DISORDER (CDD)

Marinus Pharmaceuticals | July 31, 2020

news image

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Dis...

Read More

CITIUS PHARMACEUTICALS ACHIEVES CHEMICAL MANUFACTURING AND CONTROL MILESTONES FOR MINO-LOK

Citius Pharmaceuticals | September 23, 2020

news image

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloods...

Read More

Business Insights

IKTOS AND TEIJIN PHARMA TO CO-DEVELOP NEW TECHNOLOGY FOR SMALL MOLECULE DRUG DISCOVERY

Iktos | April 07, 2022

news image

Iktos, a company specialized in Artificial Intelligence for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharma’s small molecu...

Read More

Business Insights

ITERATIVE SCOPES RECEIVES FDA CLEARANCE FOR AI-ASSISTED POLYP DETECTION DEVICE SKOUT™

Iterative Scopes | September 23, 2022

news image

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technolog...

Read More
news image

MARINUS PHARMACEUTICALS EARNS RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR GANAXOLONE TREATING CDKL5 DEFICIENCY DISORDER (CDD)

Marinus Pharmaceuticals | July 31, 2020

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Dis...

Read More
news image

CITIUS PHARMACEUTICALS ACHIEVES CHEMICAL MANUFACTURING AND CONTROL MILESTONES FOR MINO-LOK

Citius Pharmaceuticals | September 23, 2020

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has achieved a number of significant milestones over the past several weeks for Mino-Lok®. Mino-Lok is an antibiotic lock solution being developed as an adjunctive therapy for patients with central line-associated bloodstream infections (CLABSIs) or catheter-related bloods...

Read More
news image

Business Insights

IKTOS AND TEIJIN PHARMA TO CO-DEVELOP NEW TECHNOLOGY FOR SMALL MOLECULE DRUG DISCOVERY

Iktos | April 07, 2022

Iktos, a company specialized in Artificial Intelligence for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design. Under the agreement, Iktos generative modelling technology will be implemented and applied to several Teijin Pharma’s small molecu...

Read More
news image

Business Insights

ITERATIVE SCOPES RECEIVES FDA CLEARANCE FOR AI-ASSISTED POLYP DETECTION DEVICE SKOUT™

Iterative Scopes | September 23, 2022

Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions, announced that SKOUT™ has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for adults undergoing colorectal cancer screening or surveillance. SKOUT, a real-time computer-aided polyp detection device developed by Iterative Scopes, uses advanced computer vision technolog...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us